Silver nanoparticle synthesis in human ferritin by photochemical reduction.


Journal

Journal of inorganic biochemistry
ISSN: 1873-3344
Titre abrégé: J Inorg Biochem
Pays: United States
ID NLM: 7905788

Informations de publication

Date de publication:
05 2020
Historique:
received: 18 10 2019
revised: 28 01 2020
accepted: 30 01 2020
pubmed: 7 3 2020
medline: 19 5 2021
entrez: 7 3 2020
Statut: ppublish

Résumé

Ferritin is a globular hollow protein that acts as the major iron storage protein across living organisms. The 8 nm-diameter internal cavity of ferritin has been used as a nanoreactor for the synthesis of various metallic nanoparticles different to iron oxides. For this purpose, ferritin is incubated in solution with metallic ions that enter the cavity through its natural channels. Then, these ions are subjected to a reduction step to obtain highly monodisperse metallic nanoparticles, with enhanced stability and biocompatibility provided by the ferritin structure. Potential biomedical applications of ferritin-nanoparticle complex will require the use of human ferritin to provide a safer and low-risk alternative for the delivery of metallic nanoparticles into the body. However, most of the reported protocols for metallic nanoparticles synthesis uses horse spleen ferritin as nanocontainer. Previous studies have acknowledged technical difficulties with recombinant human ferritin during the synthesis of metallic nanoparticles, like protein precipitation, which is translated into low recovery yields. In this study, we tested a novel photochemical reduction method for silver nanoparticle synthesis in human recombinant ferritin and compared it with the traditional chemical reduction method. The results show that photoreduction of silver ions inside ferritin cavity provides a universal method for silver nanoparticle synthesis in both recombinant human ferritin homopolymers (Light and Heavy ferritin). Additionally, we report important parameters that account for the efficiency of the method, such as ferritin recovery yield (~60%) and ferritin‑silver nanoparticle yield (34% for H-ferritin and 17% for L-ferritin).

Identifiants

pubmed: 32142941
pii: S0162-0134(20)30044-1
doi: 10.1016/j.jinorgbio.2020.111016
pii:
doi:

Substances chimiques

Recombinant Proteins 0
Silver 3M4G523W1G
Apoferritins 9013-31-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

111016

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Italo Moglia (I)

Department of Chemical Engineering, Biotechnology and Materials, FCFM, University of Chile, Beauchef 851, Santiago, Chile; Center for Biotechnology and Bioengineering - CeBiB, FCFM, University of Chile, Beauchef 851, Santiago, Chile.

Margarita Santiago (M)

Department of Chemical Engineering, Biotechnology and Materials, FCFM, University of Chile, Beauchef 851, Santiago, Chile; Center for Biotechnology and Bioengineering - CeBiB, FCFM, University of Chile, Beauchef 851, Santiago, Chile.

Monica Soler (M)

Department of Chemical Engineering, Biotechnology and Materials, FCFM, University of Chile, Beauchef 851, Santiago, Chile.

Alvaro Olivera-Nappa (A)

Department of Chemical Engineering, Biotechnology and Materials, FCFM, University of Chile, Beauchef 851, Santiago, Chile; Center for Biotechnology and Bioengineering - CeBiB, FCFM, University of Chile, Beauchef 851, Santiago, Chile. Electronic address: aolivera@ing.uchile.cl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH